ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PRPO / dividends
EYPT (26) RPID (34) HBIO (47) BNGO (29) ⌘ Pro Terminal β†’

Precipio Inc. (PRPO) Dividend Safety Gauge & 10-Year DRIP Compounder

$17.79 -1.71% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.70

Precipio Inc. (PRPO) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $32.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRPO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $17.79 (-1.71% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PRPO ranks #810 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PRPO compare to EYPT and RPID in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRPO?
β–Ό

Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $17.70 (-0.50%)🧬 Dilution Drag (+1.64% YoY Shares)βš™οΈ Cash Engine: 5/20 (E) β€’ 1.5% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (30/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (5)Whales (3)SEC (7)Macro (9)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$35 Bull$16 Base$12 Bear
πŸ“¬ FREE PRPO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PRPO)Realized 20D OHLCV Swing Band: Β±10.3%
Deterministic 5-Pillar Attribution (30/100 Composite)
πŸ” WHY PRPO SCORES 30/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 31.3 (OVERSOLD (<32))

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) β€’ Piotroski F-Score 8/9

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
38
Grade E$22.59-3.9% Next Q
Q2 (-2Q)
35
Grade E$21.72-12.9% Next Q
Q3 (-1Q)
33
Grade E$18.91-5.9% Next Q
Current
30
Grade E$17.79-9.6% Hist 90D Ξ±
Trajectory: E (38) β†’ E (30)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PRPO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PRPO currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.10) and Max Pain ($18.68) forces dealer call-delta covering toward $35.31.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRPOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPRPO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $40,809

Est. Year-10 Shareholder Yield: $245/yr
$11.5K
Yr 1
$13.2K
Yr 2
$15.2K
Yr 3
$17.6K
Yr 4
$20.2K
Yr 5
$23.3K
Yr 6
$26.8K
Yr 7
$30.8K
Yr 8
$35.5K
Yr 9
$40.8K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRPO)

  • βœ“Walkthrough of PRPO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PRPO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.10%β–Ό DESCENDING CHANNEL
2026-11-03O $19.35H $19.35L $17.79C $17.79VOL 25.9K
RES: $31.91SUP: $15.22SMA50: $24.10SMA200: $24.94
$34.74$30.15$25.55$20.96$16.36RES $31.91SUP $15.22$17.792026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRPO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PRPO Butterfly Map β†’ + Track PRPO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +30.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRPO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PRPO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRPO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRPO)

Health Care Rank #810 of 1015 βš”οΈ EYPT vs PRPO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PRPO vs. EYPT, RPID, HBIO, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Precipio Inc. (PRPO) ranks #810 by composite RQD confidence (30/100, grade E) and #788 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, PRPO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PRPO at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRPO ACTIVE
Precipio Inc.
E 30/100 β€” 44.2% -7.9% -1.71% $32.4M Benchmark Subject
EYPT
EyePoint Inc.
E 26/100 β€” β€” -35.0% +7.58% $30.0M /eypt-vs-prpo β†’
RPID
Rapid Micro Biosystems Inc. (Class A)
E 34/100 β€” β€” -35.0% -4.50% $36.9M /rpid-vs-prpo β†’
HBIO
Harvard Bioscience Inc.
D 47/100 β€” 57.7% -35.0% -3.37% $40.5M /hbio-vs-prpo β†’
BNGO
Bionano Genomics Inc.
E 29/100 β€” 46.3% -35.0% +0.87% $16.1M /bngo-vs-prpo β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001043961 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precipio Inc. (PRPO) reported GAAP revenue of $24.2M (+30.5% vs. FY2024 revenue of $18.6M , and +57.3% cumulative change since FY2023) , GAAP net income of -$363.0K, operating cash flow of $685.0K, and free cash flow of $359.0K (+66.2% YoY). On the balance sheet, PRPO closed FY2025 with $21.3M in total assets against $47.0K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $24.2M -$363.0K $685.0K $359.0K $21.3M $47.0K
FY2024 (FY) 2024-12-31 $18.6M -$4.3M $439.0K $216.0K $17.0M $77.0K
FY2023 (FY) 2023-12-31 $15.4M -$5.9M -$3.6M -$3.6M β€” β€”

3. PRPO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $17.79 (-1.71% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PRPO ranks #810 in composite RQD confidence.

How does PRPO compare to EYPT and RPID in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRPO?

Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRPO trading relative to its 50-day, 200-day, and 52-week technical levels?

PRPO last traded at $17.79 (-1.71% on volume of 12,784 shares), positioning the stock -26.18% below its 50-day simple moving average ($24.10) and -28.67% below its 200-day simple moving average ($24.94). Across its 52-week range of $17.99 to $33.63, PRPO sits at the 0.0% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of Β±10.3% ($15.96 to $19.62).

Direct Sub-Reports: PRPO RQD Cockpit PRPO 12M Forecast PRPO Earnings & Move PRPO Dividends & DRIP PRPO Insiders & 13F PRPO Whale Options PRPO Profit Sankey PRPO News & Why
ROARABLE RATING BRIEF β€’ RQD 30/100 (E) βœ“ SEC XBRL & RQD VERIFIED

PRPO β€” Precipio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Precipio Inc. (PRPO) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $17.79 (-1.71% 1D, market capitalization $32.4M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -7.9%, gross margin of 44.2%, operating margin of -5.0%, and free cash flow yield of 1.04%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 8/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Precipio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry..0B, which is inconsistent with the $34.6M figure in the market data section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Precipio Inc. (PRPO) reported $24.2M in annual revenue (up from $18.6M in FY2024, +30.5% YoY) and -$363.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.4M revenue, -$5.9M net income) through FY2025, PRPO scaled operating cash flow to $685.0K and free cash flow to $359.0K, backed by $21.3M in total assets against $47.0K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.04% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $17.99 – $33.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -5.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), PRPO carries a macro regime beta of 1.00 and gross margin of 44.2%.

  • Key Question #1: Can PRPO sustain or expand its -5.0% operating margin and -7.9% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $24.2M and free cash flow of $359.0K, how will capital allocation balance growth reinvestment against $47.0K in total debt?
  • Key Question #3: How sensitive is PRPO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRPO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Precipio Inc. (PRPO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PRPO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRPO Bull vs. Bear Conversation Board β€” What's Your Call at $17.79?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRPO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRPO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $21.36 (+18.0%)
πŸ“Œ Pinned Debate

Revenue grew from $15.4M in FY 2023 to $24.2M in FY 2025 while operating losses narrowed from -$7.6M to -$1.2M, and the Piotroski F-Sco

Here is why I am bullish on PRPO here at $18.10: Revenue grew from $15.4M in FY 2023 to $24.2M in FY 2025 while operating losses narrowed from -$7.6M to -$1.2M, and the Piotroski F-Score of 8 out of 9 signals strong operating quality.. Compare PRPO's -5.0% operating margin and -7.9% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $17.20 are getting bought.

EarningsSniper πŸ‚ BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $18.10 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $13.76 (-24.0%)
Spot @ $18.10

With an Altman Z-Score of 0.2, ROIC of -7.9%, and an FCF yield of 1.04%, the company shows distress-zone solvency signals and weak cash

With an Altman Z-Score of 0.2, ROIC of -7.9%, and an FCF yield of 1.04%, the company shows distress-zone solvency signals and weak cash returns alongside a 3 out of 20 Whale 13F Flow score.. Look at the math on PRPO: paying current EV/EBITDA multiples for -7.9% ROIC and -5.0% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $15.93 before getting long.

LIVE TAPE